UBS AM’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.9M Sell
126,866
-19
-0% -$2.85K ﹤0.01% 945
2026
Q1
$19.4M Buy
126,885
+104,729
+473% +$16.1M ﹤0.01% 893
2025
Q4
$3.05M Buy
+22,156
New +$2.9M ﹤0.01% 1704
2022
Q1
Sell
-20,307
Closed -$1.78M 2811
2021
Q4
$1.78M Buy
20,307
+2,900
+17% +$241K ﹤0.01% 1926
2021
Q3
$1.42M Sell
17,407
-2,400
-12% -$216K ﹤0.01% 1988
2021
Q2
$1.81M Buy
19,807
+4,300
+28% +$383K ﹤0.01% 1901
2021
Q1
$1.33M Buy
15,507
+2,330
+18% +$209K ﹤0.01% 1946
2020
Q4
$1.24M Buy
13,177
+7,227
+121% +$632K ﹤0.01% 1883
2020
Q3
$517K Buy
+5,950
New +$515K ﹤0.01% 2125
2020
Q2
Sell
-397,900
Closed -$32.8M 2514
2020
Q1
$32.8M Buy
397,900
+247,600
+165% +$22.1M 0.02% 569
2019
Q4
$14.2M Sell
150,300
-42,547
-22% -$3.82M 0.01% 848
2019
Q3
$16.8M Sell
192,847
-10,043
-5% -$902K 0.01% 810
2019
Q2
$18.5M Buy
202,890
+111,880
+123% +$9.47M 0.01% 780
2019
Q1
$7.84M Sell
91,010
-5,207
-5% -$418K 0.01% 1002
2018
Q4
$7.4M Buy
96,217
+7,944
+9% +$618K 0.01% 952
2018
Q3
$6.82M Buy
88,273
+83,828
+1,886% +$6.2M 0.01% 1046
2018
Q2
$301K Buy
4,445
+141
+3% +$9.73K ﹤0.01% 2296
2018
Q1
$312K Sell
4,304
-2,514
-37% -$191K ﹤0.01% 2192
2017
Q4
$513K Sell
6,818
-25,967
-79% -$1.96M ﹤0.01% 1964
2017
Q3
$2.52M Buy
32,785
+1,358
+4% +$103K ﹤0.01% 1311
2017
Q2
$2.35M Buy
31,427
+1,063
+4% +$75.3K ﹤0.01% 1297
2017
Q1
$2.02M Sell
30,364
-9,873
-25% -$658K ﹤0.01% 1349
2016
Q4
$2.63M Sell
40,237
-3,181
-7% -$206K ﹤0.01% 1179
2016
Q3
$3.07M Sell
43,418
-2,320
-5% -$169K ﹤0.01% 1201
2016
Q2
$3.38M Sell
45,738
-39,521
-46% -$2.73M ﹤0.01% 1153
2016
Q1
$5.53M Buy
85,259
+55,147
+183% +$3.75M 0.01% 998
2015
Q4
$2.32M Sell
30,112
-154,824
-84% -$12.3M ﹤0.01% 1368
2015
Q3
$15.2M Buy
184,936
+181
+0.1% +$16.1K 0.02% 759
2015
Q2
$16.3M Buy
184,755
+4,768
+3% +$437K 0.02% 775
2015
Q1
$15.9M Buy
179,987
+63
+0% +$5.59K 0.02% 767
2014
Q4
$14.9M Sell
179,924
-13,510
-7% -$1.12M 0.01% 771
2014
Q3
$16.3M Sell
193,434
-5,578
-3% -$451K 0.02% 732
2014
Q2
$16.1M Buy
199,012
+13,348
+7% +$1.05M 0.02% 733
2014
Q1
$14.1M Sell
185,664
-8,215
-4% -$599K 0.02% 747
2013
Q4
$14M Buy
193,879
+10,781
+6% +$749K 0.02% 734
2013
Q3
$12.6M Sell
183,098
-66
-0% -$4.37K 0.02% 736
2013
Q2
$11.6M Buy
+183,164
New +$11.9M 0.02% 727

Other funds holding NVS

UBS AM's NVS Position: Q2 2026 in Review

UBS AM reduced its Novartis (NVS) stake by 0.01% in Q2 2026, selling an estimated $2.85K and leaving 126,866 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #945.

UBS AM first reported a position in NVS in Q2 2013 and has held it in 37 quarters since. The position peaked at $32.8M in Q1 2020. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • UBS AM held 126,866 shares of Novartis worth $19.9M as of Q2 2026.
  • UBS AM sold 19 Novartis shares in Q2 2026, an estimated $2.85K.
  • Novartis made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #945 holding.
  • UBS AM first reported a position in Novartis in Q2 2013 and has held it in 37 quarters since.
  • UBS AM's Novartis position peaked at $32.8M in Q1 2020.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.